Condition

Oligometastatic Prostate Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14
Recruiting7
Common interventions25
Lead sponsors shown14
Advertisement

Clinical trials

14 shown
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate CancerNCT07686016 · 2026-06-26
RECRUITING
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate CancerNCT07015138 · 2025-06-01
RECRUITING
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)NCT06387056 · 2024-04-01
RECRUITING
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative RadiotherapyNCT05560659 · 2023-12-14
RECRUITING
Maximal Tumor Eradication for Oligometastatic Prostate CancerNCT06972511 · 2023-08-20
RECRUITING
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerNCT05915442 · 2023-07-01
RECRUITING
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)NCT04610372 · 2021-07-12
RECRUITING
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)NCT07782112 · 2026-11-01
NOT_YET_RECRUITING
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate CancerNCT07490210 · 2026-05-01
NOT_YET_RECRUITING
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)NCT06060652 · 2023-05-11
UNKNOWN
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate CancerNCT04992026 · 2021-01-01
COMPLETED
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsisNCT03940235 · 2019-10-01
UNKNOWN
Phase II Study of SBRT as Treatment for Oligometastases in Prostate CancerNCT02192788 · 2014-08-01
COMPLETED
Radiotherapy for Oligometastatic Prostate CancerNCT01859221 · 2013-05-01
COMPLETED

Common interventions

Leading sponsors

Trial status mix

RECRUITING7
COMPLETED3
NOT_YET_RECRUITING2
UNKNOWN2

Phase mix

PHASE27
NA4
PHASE32
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.